Assessment | Biopsychology | Comparative | Cognitive | Developmental | Language | Individual differences | Personality | Philosophy | Social |
Methods | Statistics | Clinical | Educational | Industrial | Professional items | World psychology |

Biological: Behavioural genetics · Evolutionary psychology · Neuroanatomy · Neurochemistry · Neuroendocrinology · Neuroscience · Psychoneuroimmunology · Physiological Psychology · Psychopharmacology (Index, Outline)

Monoamine transporters, as the name implies, transfer monoamine neurotransmitters in or out of a cell.

There are several different monoamine transporters.

DAT, NET and SERT are related to each other and they all consist of a structure of 12 transmembrane helices.

Drug action[edit | edit source]

Many drugs, such as antidepressants and psychoactives effect the monoamine transporters.

Modern antidepressants typically work by enhancing serotonergic or noradrenergic neurotransmission by binding to the SERT or NET, and thereby inhibiting reuptake of serotonin and/or norepinephrine and raising active levels in the synapse. Fluoxetine is a selective serotonin reuptake inhibitor and works as a SERT antagonist. Reboxetine is a norepinephrine reuptake inhibitor and works as a NET antagonist.

The euphoric and addictive properties of amphetamine, methamphetamine and cocaine are thought to come from their ability to inhibit DAT activity.

See also[edit | edit source]

References[edit | edit source]

G.E. Torres, R.R. Gainetdinov and M.G. Caron (2003). Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neuroscience 4: 13-25.

This page uses Creative Commons Licensed content from Wikipedia (view authors).
Community content is available under CC-BY-SA unless otherwise noted.